Clinical Trial Update: Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation [NA]

View source ↗

Summary

A clinical trial evaluating whether dapagliflozin can prevent recurrence of atrial fibrillation after catheter ablation; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Dapagliflozin (Farxiga) (dapagliflozin)

Snippet

Sponsor: Xu Liu | Conditions: Atrial Fibrillation (AF) | NA | Status: NOT_YET_RECRUITING